Диссертация (1139681), страница 39
Текст из файла (страница 39)
Exp. Ther. -1996. -Vol. 44. -P. 247-254.111. Berlowitz D.R., Ash A.S., Hickey E.C. Inadequate management ofblood pressure in a hypertensive population. // N. Engl. J. Med. -1998. –Vol.339. –P. 1957-1963.245112. Bidwell J., Keen L., Gallageher G. Cytokine gene polymorphism inhuman disease: on-line databases.
// Genes Immun. -2009. -Vol. 1. -P. 3-19.113. Black H.R. Management of patients with refractory hypertension in:book Hypertension primer: The essential of high blood pressure. / Ed. byJ.L. Izzo, H.R. Black. — Dallas: AHA. -2003. -P 552.114. Bogdahh V., Becker G., Winkler J., Greiner K. Transcranial colorcoden real-time sonography in adults. // Stroke. -1990. -Vol.
91. N. 12.-P. 1680-1688.115. Brasselet C., Durand E., Addad F. Collagen and elastin cross-linking:a mechanism of constrictive remodeling after arterial injury. // Am. J. Physiol. Heart Circ. Physiol. –2010. -Vol. 289. –n. 5. –H 2228–H2233.116. Brown M.A., Buddle M.L., Martin A. Is resistant hypertension reallyresistant? // Am. J. Hypertens. -2001. -Vol.14.
–n. 12. -P. 1263-1269.117. Burke B.E., Neuenschwander R., Olson R.D. Randomized, doubleblind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. // South. Med. J. -2001.-Vol. 94. –n. 11. -P. 1112–1117.118. Burton G.W., Traber M.G. Vitamin E: antioxidant activity, biokineticsand bioavailability. // Annu. Rev. Nutr. -1990. -Vol.10. -P. 357–382.119.
Cadenas E., Hochstein P. P., Ernster L. Pro- and antioxidant functionsof quinones and quinone reductases in mammalian cells. //Adv. Enzymol.Relat. Areas Mol. Biol. -1992. -Vol. 65. -P. 97–147.120. Cai Z., Manalo D.J., Wei G. et al. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemiareperfusion injury. // Circulation. -2003. -Vol. 108. -P. 79-85.121. Calhoun D.A.
Resistant or difficult-to-treat hypertension. // J. Clin.Hypertens. -2006. –n. 8. -P. 181-186.122. Calhoun D.A., Jones D., Textor S. Resistant Hypertension: Diagnosis,Evaluation, and Treatment. A Scientific Statement from the American HeartAssociation Professionall Education Committee of the Council for HighBlood Pressure Research.
// Hypertension. -2008. –P. 51. -1403-1419.246123. Chan C.K., Head G.A. Relative importance of central imidazoline receptors for antihypertensive effects of moxonidine and rilmenidine. // J. Hypertens. -1996. -Vol.14. -P. 855-864.124. Chobanian A.V., Bakris G.L., Black H.R. Seventh report of the JointNational Committee on Prevention, Detection, Evaluation and Treatment ofHigh Blood Pressure. // Hypertension. -2003.
-Vol.42. –n. 6. -P. 1206–1252.125. Clapp B.R., Hirschfield G.M., Storry C. Inflammation and endothelialfunction: direct vascular effects of human C-reactive protein on nitric oxidebioavailailability. // Circulation. -2005. -Vol.111. –n. 12. –P. 1530–1536.126. Coca A. Economic benefits of treating high-risk hypertension withangiotensin II receptor antagonists (blockers). // Clinical Drug Investigation.-2008. -Vol.28.
–n. 4. -P. 211–220.127. Cottone S., Vadala L., Guarnery M. Relation of C-reactive protein tooxidative stress and to endothelial dysfunction in essential hypertension. //J. Hypertension. -2005. -Vol. 23. –n. 2. –S. 58.128. Cruz-González I., Corral Е., Sánchez-Ledesma М. Association between -T786C NOS3 polymorphism and resistant hypertension: a prospective cohort study. // BMC Cardiovasc. Disord. -2009. –Vol.9. –n.
35.-P. 131-142.129. Cushman W.C., Ford C.E., Cutler J.A. et al.; for the ALLHAT Collaborative Research Group (2002) Success and predictors of blood pressurecontrol in diverse North American settings: the Antihypertensive and LipidLowering and Treatment to Prevent Heart Attack Trial (ALLHAT). // J.Clin. Hypertens. -2002. –Vol.4. –n. 6. –P. 393–404.130. Davis S. Transcranial doppler ultrasonography and cerebral bloodflow / Babikian V.L., Wechsler L.R. Transcranial doppler ultrasonography.-Mosby -Year Book, Inc.
-1993. -P. 69-79.131. De Brabander A., Deberdt W. Effect of hydroxizyne on attentijn andmemory. // Human Psychopharmacology. -1990. –Vol. 341. –P. 357–362.132. Dechend R., Homuth V., Wallukat G. AT1 receptor agonistic anti-247bodies from preeclamptic patients cause vascular cells to express tissue factor. // Circulation.
-2000. –Vol. 101. -P. 2382–2387.133. Deter H.C. Towards a new strategy to implement psychosomaticknowledge in medical practice. // Biopsychosoc. Med. -2008. –n. 2. -P. 1-2.134. Deter H. C., Blum B., Schwarz U. Cardiovascular reactivity in patients with essential or renal hypertension under standardized mental stress.// Clin. Exp. Hypertens. -2007. -Vol. 29.
–n. 5. -P. 301-310.135. Detrano R., Guerci A.D., Carr J.J. Coronary calcium as a predictor ofcoronary events in four racial or ethnic groups. // N. Engl. J. Med. -2008.-Vol. 358.-n. 13. -P. 1336–1345.136. Dickinson H.O., Mason J.M., Nicolson D.J., Campbell F., Beyer F.R.Lifestyle interventions to reduce raised blood pressure: a systematic reviewof randomized controlled trials. // J. Hypertens.
-2006. -Vol.24. –P. 215-233.137. Digiesi V., Cantini F., Brodbeck D. Effect of conexyme Q10 on essential arterial hypertension. // Curr Ther Res. -1990. -Vol. 47. –n. 5.-P. 841–845.138. Dikstein K., Manhenke C., Aarsland T. The effect of chronic, sustained-release moxonidine therapy on clinical and neurohumoral status inpatients with heart failure. // Int. J. Cardiol. -2000. -Vol.75.
-P. 167-176.139. Eide I.K., Torjesen P.A., Drolsum A., Babovic A., Lilledahl N.P.Low-renin status in therapy-resistant hypertension: a clue to efficient treatment // J. Hypertens. -2004. -Vol. 22. -P. 2217-2226.140. Ernsberger P., Damon T.H., Graff L.M. Moxonidine, a centrally acting anti-hypertensive agent, is a selective ligand for Il-imidazoline sites. //J. Pharmacol. Exp. Ther. -1993. -Vol.
264. -P. 172-182.141. Feldman A.M., Brostow M.R., Parmley W.W. Effects of vesnarinoneon norbidity andmortality in patients with heart failure. // New Engl. J. Med.-1993. -Vol. 329. -P. 149-155.142. Ferrara N., Gerber H.P. The role of vascular endothelial growth factorin angiogenesis. // Acta Haematol. -2002. –Vol. 106. –n. 4. –P. 148–156.248143. Ferreri M., Hantouche T., Billardon M.
Interet de l’hydroxizynedansdes trouble d’anxietegeneralisee: etude controlee en double aveugle versusplacebo. // L’encephale. -1994. -Vol. 20. -P. 785–791.144. Folstein M.F., Folstein S.E., McHugh P.R. «Mini-mental state». Apractical method for grading the cognitive state of patients for the clinician.// Journal of Psychiatric Research. -1975. -Vol.12. –n.
3. -P. 189–198.145. Forsmark-Andree P., Ernster L. Evidence for a protective effect of endogenous ubiquinol against oxidative damage to mitochondrial protein andDNA during lipid peroxidation. // Mol. Asp. Med. -1994. -Vol. 15.– S. 73–S81.146. Frohlich E.D. Classification of resistant hypertension. // Hypertension.-1988. –n. 11 (Suppl.
II). -P. 67-70.147. Fromm M.F., Schmidt B.M., Pahl A. CYP3A5 genotype is associatedwith elevated blood pressure. // Pharmacogenet. Genomics. -2005. –Vol. 15.–n. 10. -P. 737–741.148. Garg J.P., Elliott W.J., Folker A., Izhar M., Black H.R., for the RUSHHypertension Service. Resistant hypertension revisited: a comparison of 2university-based cohorts. // Am. J. Hypertens. -2005.
-Vol. 18. -P. 619-626.149. Goldberg R.J., Larson M., Levy D. Factors associated with survival to75 years of age in middle- aged men and women. // Arch. Intern. Med.–2006. –Vol. 156. –P.505–510.150. Grunfeld S., Hamilton C.A., Mesaros S.
Role of superoxide in the depressed nitric oxide production by the endothelium of genetically hypertensive rats. // Hypertension. -2009. -Vol. 26 (6 Pt. 1). –P. 854–857.151. Hajjar I., Kotchen T.A. Trends in prevalence, awareness, treatment,and control of hypertension in the United States, 1988–2000. // JAMA.-2003. -Vol. 290. -P.
199–206.152. Hamilton S.J., Chew G.T., Watts G.F. Coenzyme Q10 improves endothelial dysfunction in statin-treated type 2 diabetic patients. // Diabetes Care.-2009. -Vol. 32. –n. 5. -P. 810–812.249153. Hannila-Handelberg T., Kontula K., Tikkanen I. Common variants ofthe beta and gamma subunits of the epithelial sodium channel and their relation to the plasma renin and aldosterone levels in essential hypertension. //BMC Med. Genet. -2005. -Vol. 6.
–n. 4. –P. 27-33.154. Harron D. Clinical pharmacology of imidazolines and related compounds. // Fundam Clin. Pharmacol. -1992. –n. 6. –S. 41-44.155. He F.J., MacGregor G.A. How far should salt intake be reduced? //Hypertension. -2009. -Vol. 42. -P. 1093-1099.156. Hermida R.C., Ayala D.E., Calvo C., Lopez J.E., Mojon A., FontaoEffects of time of day of treatment on ambulatory blood pressure pattern ofpatients with resistant hypertension. // Hypertension. -2005. -Vol. 46.-P.
1053-1059.157. Hill M.N., Miller N.H. Adherence to antihypertensive therapy. // Hypertension: A Companion to Brenner and Rector’s. The Kidney. / Ed. by S.Oparil, А. Weber. -St. Louis. -2000. –P. 757.158. Ho H., Pinto F.A., Hall S.D. Association between the CYP3A5 genotype and blood pressure. // Hypertension. -2005. -Vol. 45. –n. 2.–P. 294–298.159. Holmes K., Owain L., Angharad M., Cross M. Vascular endothelialgrowth factor receptor-2: Structure, function, intracellular signalling andtherapeutic inhibition.
// Cellular Signalling. -2007. -Vol. 19. –n. 10.-P. 2003–2012.160. Huang Z., Willett W.C., Manson J.E. Body weight, weight change andrisk for hypertension in women // Ann. Intern. Med. -1998. -Vol. 128.–P. 81-88.161. Johns M.B., Paulus-Thomas J.E. Get expression of renin an-giotensinsystem in human tissues quantitativa analysis by the polymeras chain riaction. // Anal Biochem. -1989. -Vol. 180. -P. 276-278.162. Johnson A.G. NSAIDs’ and Blood Pressure: Clinical Importance forOlder Patients // Drugs &Aging. -1998.
-12(1). -P. 17-26.250163. Kaplan N., Victor G.R. Kaplan’s Clinical Hypertension. // -10th edition: Lippincott Williams &Wilkins. -2009. –P. 560.164. Kaplan N. Systolic Blood Pressure a determinant of Comorbidity. //-Dallas, USA: Sciense Press. -2004. –P. 52.165. Kaplan N.M., Izzo J.L. Jr. Refractory hypertension. In: Izzo J.L. Jr,Black H.R., eds.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
